- Home
- INBX vs SANA Comparison
INBX vs SANA Comparison
Compare INBX & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBX | SANA |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.4B |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INBX | SANA |
|---|---|---|
| Price | $69.47 | $3.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 133.4K | ★ 1.9M |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 649.90 | 17.24 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $200,000.00 | N/A |
| Revenue This Year | $563.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.81 | $1.27 |
| 52 Week High | $94.57 | $6.55 |
Technical Indicators
Market Signals| Indicator | INBX | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 29.46 |
| Support Level | $28.54 | $2.85 |
| Resistance Level | $85.97 | $3.24 |
| Average True Range (ATR) | 4.58 | 0.26 |
| MACD | -1.21 | -0.09 |
| Stochastic Oscillator | 10.10 | 6.52 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.